BNE Share Price

Open 0.01 Change Price %
High 0.01 1 Day 0.00 0.00
Low 0.01 1 Week 0.00 0.00
Close 0.03 1 Month 0.00 0.00
Volume 369501 1 Year 0.02 200.00
52 Week High 0.01
52 Week Low 0.01
BNE Important Levels
Resistance 2 0.03
Resistance 1 0.03
Pivot 0.02
Support 1 0.03
Support 2 0.03
ASX Australia Most Active Stocks
AGO 0.02 0.00%
AGO 0.02 0.00%
AGO 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
TEG 0.05 0.00%
TEG 0.05 0.00%
TEG 0.05 0.00%
AKK 0.01 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
IMU 0.02 100.00%
IMU 0.02 100.00%
PMQ 0.03 50.00%
ARD 0.03 50.00%
ARD 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
EXG 0.03 50.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
AVD 0.01 -50.00%
AVD 0.01 -50.00%
AVD 0.01 -50.00%
SRX 16.00 -37.23%
SRX 16.00 -37.23%
More..

Bone Medical Ltd (ASX: BNE)

BNE Technical Analysis 5
As on 9th Jun 2016 BNE Share Price closed @ 0.03 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.01 & Strong Buy for SHORT-TERM with Stoploss of 0.01 we also expect STOCK to react on Following IMPORTANT LEVELS.
BNE Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
BNE Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.bone-ltd.com
BNE Address
BNE
C/- Ledger Corporate
Level 3
West Perth, WA 6005
Australia
Phone: 61 8 9468 0154
Fax: 61 8 9322 4946
BNE Latest News
Interactive Technical Analysis Chart Bone Medical Ltd ( BNE ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Bone Medical Ltd
BNE Business Profile
Bone Medical Limited, a specialty biopharmaceutical company, develops therapeutics to prevent and/or treat bone and joint diseases and conditions, primarily osteoporosis, osteoarthritis, and rheumatoid arthritis. The company’s product pipeline consists of Phase II clinical-stage programs and four preclinical programs. Its priority products include CaPTHymone, an oral parathyroid hormone for the treatment of osteoporosis; Capsitonin, an oral calcitonin for the treatment of osteoarthritis pain; and BN006, a synthetic oligopeptide with selective TNF-a and IL-6 inhibitory mechanism and the potential for oral administration. The company is based in West Perth, Australia.